The research, led by Yun He and Ping Li along with colleagues at Zhejiang Cancer Hospital in Hangzhou, China, enrolled 199 women who had undergone breast MRI for evaluation of non-mass enhancement lesions. Of these patients, 76 ultimately proved to have benign lesions while 123 had malignant disease confirmed by pathology. The goal was straightforward but ambitious: identify which clinical and imaging characteristics genuinely separate benign from malignant non-mass enhancement, and then distill those characteristics into a scoring system that a radiologist could apply in everyday practice without needing specialized software or advanced computational tools.

The methodological approach was rigorous and systematic. The researchers first used the Mann-Whitney U test to compare the ages of women in the benign and malignant groups, since age is one of the most fundamental risk factors in breast cancer. They then applied nonparametric statistical tests to examine differences between the two groups across a comprehensive battery of imaging variables, including the type of glandular tissue in the breast, the degree of background parenchymal enhancement, which reflects how much normal breast tissue takes up contrast on its own, the signal characteristics of lesions on T1-weighted, T2-weighted, and diffusion-weighted imaging, the morphological distribution of the enhancement, the enhancement patterns of the lesions themselves, the early enhancement rate, and the shape of the time-intensity curve, a dynamic measure of how quickly contrast flows into and out of the lesion over the course of the scan.

The univariate analysis revealed significant differences between benign and malignant lesions across several of these dimensions. Age mattered, as expected. The signal patterns observed on T1-weighted, T2-weighted, and diffusion-weighted imaging all showed discriminatory power, as did the morphological distribution of the enhancement, the enhancement pattern of the lesion, and the early fast enhancement rate. These findings align with established radiological principles: malignant tissue tends to have different water content and cellularity than benign tissue, which alters its appearance on different MRI sequences, and malignant lesions typically show more aggressive and disordered vascularization, producing faster and more intense contrast uptake.

To move from association to prediction, the team fed the statistically significant univariate variables into multivariable logistic regression, a technique that determines which factors remain independently predictive when all others are accounted for. Five features emerged as independent predictors of malignancy in non-mass enhancement lesions: age greater than 40 years, diffusion restriction on diffusion-weighted imaging, segmental distribution of the lesion, diffuse distribution of the lesion, and an early fast enhancement rate. Each of these predictors carried an odds ratio quantifying how strongly it associated with malignancy, and the researchers used the magnitude of these odds ratios as the basis for assigning points in their scoring system. This approach gives the score an intuitive logic, with features that carry greater statistical weight contributing more to a patient’s total score.

The performance of the resulting score was encouraging, particularly on one critical dimension. Measured by the area under the receiver operating characteristic curve, a standard metric of diagnostic discrimination where 0.5 represents chance and 1.0 represents perfection, the scoring system achieved an AUC of 0.843. More strikingly, the system demonstrated a specificity of 90.79 percent, meaning that when the score indicates a lesion is benign, that assessment is very likely correct. The sensitivity was moderate at 62.6 percent, indicating that the score catches a meaningful but incomplete proportion of malignant lesions. In practical terms, this profile suggests the tool may be most valuable for identifying patients whose non-mass enhancement lesions are very likely benign, potentially sparing them unnecessary biopsy, while ensuring that unclear cases still proceed to tissue sampling.

The clinical significance of this work becomes clearer when considering the wider context of breast MRI screening. Breast MRI is increasingly used in high-risk screening programs and in the evaluation of patients with newly diagnosed cancer, and non-mass enhancement is a common finding in these settings. Because such lesions cannot be reliably characterized by ultrasound or mammography, radiologists often face a dilemma: recommend biopsy with its associated costs, anxiety, and procedural risks, or recommend follow-up imaging with the possibility of delaying a cancer diagnosis. A validated scoring system built from features already visible on a standard clinical MRI, requiring no additional imaging sequences or expensive post-processing, offers a practical middle path that could reduce unnecessary interventions without compromising safety.

The technical underpinnings of the score also merit attention. Diffusion-weighted imaging reflects the random motion of water molecules within tissue, and restriction of that motion is a hallmark of highly cellular tissue, which is characteristic of many tumors. Segmental distribution, in which enhancement follows the branching architecture of a ductal system, and diffuse distribution are morphological patterns long recognized in the Breast Imaging Reporting and Data System lexicon as suspicious, while the early enhancement rate captures the kinetic behavior of contrast uptake that reflects tumor angiogenesis. By combining these imaging features with the simple clinical variable of patient age, the scoring system leverages complementary streams of information in a way that mirrors how experienced radiologists reason through difficult cases, but in a standardized and reproducible format.

The authors are careful to frame their findings as a foundation rather than a finished clinical tool. They note that the scoring system has good discriminative performance with high specificity and moderate sensitivity, and that with further refinement and larger datasets it may serve as a useful diagnostic aid in clinical practice. The single-center design and the moderate sample size of 199 patients mean that external validation in independent, more diverse populations will be essential before widespread adoption. Future work could also explore combining the score with emerging computational approaches, including machine learning models trained on radiomic features, potentially pushing sensitivity higher while preserving the impressive specificity achieved here.

Nevertheless, the study represents a meaningful step toward more rational, evidence-based management of one of breast radiology’s most persistent diagnostic gray zones. As MRI use in breast care continues to expand worldwide, tools that convert complex imaging findings into clear, actionable risk estimates will only grow in importance. For the many women each year who receive an ambiguous non-mass enhancement finding on breast MRI, a simple score that reliably separates the benign from the malignant could translate into fewer unnecessary biopsies, faster diagnoses for those who need treatment, and a meaningful reduction in the anxiety that accompanies uncertainty. The work by He, Li, and their colleagues demonstrates that the raw ingredients for such a tool already exist within a standard clinical MRI examination, waiting only to be systematically assembled and validated.

Subject of Research: Development of a clinical-radiological MRI-based scoring system to predict benignity and malignancy of non-mass enhancement breast lesions

Article Title: A clinical-radiological MRI-based combined scoring system for predicting benignity and malignancy of non-mass enhancement breast lesions

Article References: He, Y., Li, P., Nan, S., Dai, G., Wang, X., Wei, Y., & Deng, X. (2026). A clinical-radiological MRI-based combined scoring system for predicting benignity and malignancy of non-mass enhancement breast lesions. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02830-1

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02830-1

Keywords: breast cancer, breast MRI, non-mass enhancement, scoring system, diffusion-weighted imaging, logistic regression, diagnostic specificity, BMC Medical Imaging, radiology, lesion characterization, dynamic contrast-enhanced MRI, clinical prediction

The technique, whose full name is Deep-learning Enabled Precise Imaging via multi-Contrast multi-shoT EPI for Accelerated head scan, was evaluated in a study published in BMC Medical Imaging. Rather than accelerating only a single imaging sequence, DEPICTA uses an echo-planar imaging, or EPI, framework combined with deep learning reconstruction to deliver multiple clinically important contrast weightings—T1-FLAIR, T2-weighted, T2-FLAIR, and diffusion-weighted imaging—within a single ultrafast session. EPI is one of the fastest acquisition strategies available to MRI physicists because it collects an entire two-dimensional image from a single excitation, but it has historically suffered from geometric distortion and blurring. The innovation of DEPICTA lies in pairing a multi-shot EPI readout with neural-network-based reconstruction that fills in the missing spatial and contrast information left by aggressive undersampling of the raw data.

The study enrolled 124 consecutive patients who presented with a clinical indication for brain MRI between August and September 2025. Each participant underwent both a conventional brain MRI protocol and the ultrafast DEPICTA examination, allowing the researchers to compare the two approaches head to head in the same individuals. The cohort had a mean age of 49 years with a standard deviation of 22, and comprised 64 men and 60 women—a spread of ages and indications that the investigators argue reflects the reality of a working radiology department rather than the idealized conditions of a laboratory study. Because the design was prospective, the DEPICTA acquisition was planned in advance rather than applied retrospectively to archived scans, which strengthens the claim that the results are achievable in routine clinical practice.

The headline result is deceptively simple: DEPICTA achieved a total acquisition time of 1 minute and 27 seconds for the multi-contrast brain examination. That figure places the entire scan comfortably within the 100-second threshold set by the study title and represents a dramatic compression relative to conventional protocols, which typically allocate several minutes to each individual contrast sequence. In the ultrafast framework, the multi-shot EPI readout gathers data from multiple contrasts in a coordinated fashion, and the deep learning reconstruction model, trained to recognize the relationship between undersampled and fully sampled data, synthesizes images that would otherwise be unattainable at such speed. The significance is not merely convenience. Shorter scans reduce motion artifacts, ease the burden on claustrophobic or uncooperative patients, and open the door to MRI for populations—such as critically ill patients in intensive care units, confused elderly patients, or restless children—for whom prolonged examinations have been impractical or impossible.

Of course, speed alone is worthless if the images cannot be trusted, so the investigators subjected the ultrafast scans to rigorous qualitative and quantitative scrutiny. Two neuroradiologists independently scored overall image quality, gray-white matter differentiation, and the presence of artifacts, without knowledge of each other’s assessments. Their verdicts were nuanced. On overall image quality and gray-white matter differentiation, the ultrafast scans scored lower than conventional MRI—an expected consequence of aggressive acceleration—but remained in the range the study characterized as sufficient for clinical use. In other words, the deep learning reconstructions traded a measure of fine tissue contrast for a massive gain in acquisition speed, yet the images still delivered the diagnostic fundamentals that radiologists need.

Notably, on two crucial dimensions the ultrafast technique actually outperformed the conventional protocol. DEPICTA images showed fewer artifacts and higher signal-to-noise ratio on both T1-FLAIR and diffusion-weighted imaging compared with their conventional counterparts, differences that reached statistical significance at P < 0.05. This finding is arguably the most surprising of the study. Diffusion-weighted imaging, which is indispensable for detecting acute stroke, is exquisitely sensitive to motion, and the conventional acquisition of DWI is a frequent casualty of patient movement. By collapsing the acquisition window to seconds and using learned reconstruction to suppress noise, the ultrafast approach produced cleaner, sharper diffusion images precisely where conventional MRI is most fragile. Higher signal-to-noise ratio means the deep learning reconstruction is not merely hallucinating plausible anatomy; it is consolidating genuine signal into images that rival, and in some respects exceed, those built from far more data.

Beyond radiologists’ subjective impressions, the team examined whether measurements taken from ultrafast images could be trusted as surrogate quantities for clinical decision-making. They measured lesion sizes, apparent diffusion coefficient values within lesions—a quantitative marker of water diffusion used to characterize stroke and tumors—and the widths of the lateral, third, and fourth ventricles, which serve as indirect indicators of intracranial pressure and hydrocephalus. The ultrafast measurements agreed well with those from conventional MRI for lesion size, lesion ADC, and the width of the lateral and third ventricles, demonstrating the quantitative comparability that regulators and clinicians would require before adopting such a technique for serial monitoring. The one exception was the width of the fourth ventricle, where the two methods diverged significantly, with a P value of 0.006. The authors note this single discordance as an honest limitation, likely attributable to the small size of the fourth ventricle and the resolution constraints of the accelerated acquisition in that region.

The study also included a T2*-weighted and susceptibility-weighted module in the DEPICTA protocol, which offers the potential to detect microbleeds and venous abnormalities. However, the researchers explicitly excluded this module from their comparative image-quality and quantitative analyses, framing the full multi-contrast capability as promising but not yet validated at the level of the other sequences. That methodological restraint signals a careful, staged approach: the team is claiming feasibility for the validated contrasts while flagging the more exotic components of the protocol for future evaluation. It is a reminder that in medical imaging, enthusiasm must always be tempered by the discipline of head-to-head validation against the established standard.

The implications of the study extend well beyond Huashan Hospital. If a complete multi-contrast brain MRI can be delivered in under 90 seconds, the economics of neuroimaging begin to change. Scanner throughput could increase substantially, shortening waiting lists in overburdened health systems. Emergency departments could integrate near-instant brain MRI into acute stroke pathways, where every minute of delayed diagnosis translates into lost neurons. Patients in intensive care units, who currently must often be transported with ventilators and monitoring equipment into the magnet room for lengthy scans, could be imaged with less physiological risk. And populations historically excluded from MRI—patients with dementia who cannot follow instructions, young children who would otherwise require sedation—become plausible candidates for high-quality imaging because even brief cooperation is enough. The deep learning reconstruction also carries challenges of its own, since neural networks can introduce subtle biases and must be validated across diverse populations, scanner vendors, and disease spectra before widespread deployment.

The research was approved by the ethical board of Huashan Hospital, Fudan University, conducted with written informed consent, and adhered to the Declaration of Helsinki. It was supported by the National Natural Science Foundation of China under grant 82271966 and the Explorers Program of Shanghai under grant 24TS1410800. The corresponding authors are Yiping Lu and Bo Yin of the Department of Radiology at Huashan Hospital, and the study was a collaboration among co-first authors Mengdi Gao, Nan Mei, Jie Qin, Qirui Fu, and Xuanxuan Li, alongside Jing Du, Ke Sun, and Yiping Lu. Published open access, the work invites replication at other centers—a necessary step before an 87-second brain MRI moves from feasibility study to daily practice. For now, the message is clear: the era of the hundred-second brain scan is no longer hypothetical, and it has been delivered not by a bigger magnet but by an algorithm that knows what to do with less.

Subject of Research: Prospective feasibility of deep learning reconstructed ultrafast multi-contrast brain MRI completed within 100 seconds

Article Title: Ultrafast brain MRI within 100 s based on deep learning reconstruction: a prospective feasibility study

Article References: Ultrafast brain MRI within 100 s based on deep learning reconstruction: a prospective feasibility study. (n.d.). https://doi.org/10.1186/s12880-026-02778-2

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02778-2

Keywords: brain MRI, deep learning, ultrafast MRI, DEPICTA, echo-planar imaging, image reconstruction, BMC Medical Imaging, diffusion-weighted imaging, radiology, medical imaging, Huashan Hospital, MRI acceleration